Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Home

Cost-Effectiveness and Clinical Utility of Pancreatic Cancer Non-Invasive Test in New-Onset Diabetes

ClearNote Health
July 6, 2026

5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages

ClearNote Health
February 2, 2026

Pilot study demonstrating changes in DNA hydroxymethylation enable detection of multiple cancers in plasma cell-free DNA

ClearNote Health
February 2, 2026

Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA

ClearNote Health
February 2, 2026

A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation

ClearNote Health
February 2, 2026

The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia

ClearNote Health
February 2, 2026

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

ClearNote Health
February 2, 2026

Epigenomic Blood-Based Early Detection of Pancreatic Cancer Employing Cell-Free DNA

ClearNote Health
February 2, 2026

Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non- small cell lung cancer

ClearNote Health
February 2, 2026

Analytical Validation of an Early Detection Pancreatic Cancer Test Using 5-Hydroxymethylation Signatures

ClearNote Health
February 2, 2026

Posts pagination

1 2
ClearNote Health logo

Empowering early cancer detection.

Order Test
Company
  • About Us
  • Leadership Team
  • Our News
  • Careers
  • Contact Us
Solutions
  • Avantect Pancreatic Cancer Test
  • Avantect Ovarian Cancer Test
  • Virtuoso Epigenomics Platform
Stay Informed

Get the latest research and announcements from ClearNote Health. Follow us:

Important information: 
The Virtuoso platform is for research use only. Not for use in diagnostic procedures.

The Avantect Pancreatic and Ovarian Cancer Tests are early detection tests. The tests do not establish a diagnosis of pancreatic or ovarian cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic or ovarian cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic or ovarian cancers will be detected. Some patients with pancreatic or ovarian cancer may have a “Pancreatic/Ovarian Cancer Signal not detected” result. Some patients without pancreatic or ovarian cancer may have a “Pancreatic/Ovarian Cancer Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no pancreatic or ovarian cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.

The tests were developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and have not been cleared or approved by the US Food and Drug Administration (FDA).

Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

©2026 ClearNote Health, All Rights Reserved.

Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

  • Privacy Policy
  • Terms of Use
  • Billing rights & protections
  • Cookie Preferences